Database : MEDLINE
Search on : budesonide [Words]
References found : 5585 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 559 go to page                         

  1 / 5585 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29353017
[Au] Autor:Naeem M; Oshi MA; Kim J; Lee J; Cao J; Nurhasni H; Im E; Jung Y; Yoo JW
[Ad] Address:College of Pharmacy, Pusan National University, Busan, South Korea.
[Ti] Title:pH-triggered surface charge-reversal nanoparticles alleviate experimental murine colitis via selective accumulation in inflamed colon regions.
[So] Source:Nanomedicine;14(3):823-834, 2018 Jan 17.
[Is] ISSN:1549-9642
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:In this study, we developed pH-triggered surface charge-reversal lipid nanoparticles (LNPs), loaded with budesonide, which could precisely deliver the drug to inflamed colon segments for the treatment of ulcerative colitis. Polyethyleneimine (PEI) was used to render LNPs cationic (PEI-LNPs), and Eudragit® S100 (ES) was coated on PEI-LNPs to obtain pH-triggered charge-reversal LNPs (ES-PEI-LNPs). ES coating avoided a burst drug release under acidic conditions mimicking the stomach and early small intestine environments and showed a sustained release in the colon. The surface charge of ES-PEI-LNPs switched from negative to positive under colonic conditions owing to pH-triggered removal of the ES coating. Bioimaging of the mouse gastrointestinal tract and confocal analysis of colon tissues revealed that ES-PEI-LNPs selectively accumulated in an inflamed colon. Furthermore, ES-PEI-LNPs mitigated experimental colitis in mice. These results suggest that the pH-triggered charge-reversal LNPs could be a promising drug carrier for ulcerative colitis therapy and other colon-targeted treatments.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  2 / 5585 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29486562
[Au] Autor:Eleftheriadis GK; Akrivou M; Bouropoulos N; Tsibouklis J; Vizirianakis IS; Fatouros DG
[Ad] Address:Laboratory of Pharmaceutical Technology, School of Pharmacy , Aristotle University of Thessaloniki , 54124 Thessaloniki , Greece.
[Ti] Title:Polymer-Lipid Microparticles for Pulmonary Delivery.
[So] Source:Langmuir;, 2018 Mar 09.
[Is] ISSN:1520-5827
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Toward engineering approaches that are designed to optimize the particle size, morphology, and mucoadhesion behavior of the particulate component of inhaler formulations, this paper presents the preparation, physicochemical characterization, and preliminary in vitro evaluation of multicomponent polymer-lipid systems that are based on "spray-drying engineered" α-lactose monohydrate microparticles. The formulations combine an active (budesonide) with a lung surfactant (dipalmitoylphosphatidylcholine) and with materials that are known for their desirable effects on morphology (polyvinyl alcohol), aerosolization (l-leucine), and mucoadhesion (chitosan). The effect of the composition of formulations on the morphology, distribution, and in vitro mucoadhesion profiles is presented along with "Calu-3 cell monolayers" data that indicate good cytocompatibility and also with simulated-lung-fluid data that are consistent with the therapeutically useful release of budesonide.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher
[do] DOI:10.1021/acs.langmuir.7b03645

  3 / 5585 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29407486
[Au] Autor:Kim SR; Song JH; Ahn JH; Lee GS; Ahn H; Yoon SI; Kang SG; Kim PH; Jeon SM; Choi EJ; Shin S; Cha Y; Cho S; Kim DE; Chang SY; Ko HJ
[Ad] Address:Laboratory of Microbiology and Immunology, College of Pharmacy, Kangwon National University, Chuncheon 24341, Republic of Korea.
[Ti] Title:Antiviral and anti-inflammatory activity of budesonide against human rhinovirus infection mediated via autophagy activation.
[So] Source:Antiviral Res;151:87-96, 2018 Mar.
[Is] ISSN:1872-9096
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:Human rhinovirus (HRV) infection causes more than 80% of all common colds and is associated with severe complications in patients with asthma and chronic obstructive pulmonary disease. To identify antiviral drug against HRV infection, we screened 800 FDA-approved drugs and found budesonide as one of the possible drug candidates. Budesonide is a corticosteroid, which is commonly used to prevent exacerbation of asthma and symptoms of common cold. Budesonide specifically protects host cells from cytotoxicity following HRV infection, which depend on the expression of glucocorticoid receptor. Intranasal administration of budesonide lowered the pulmonary HRV load and the levels of IL-1ß cytokine leading to decreased lung inflammation. Budesonide regulates IL-1ß production following HRV infection independent of inflammasome activation. Instead, budesonide induces mitochondrial reactive oxygen species followed by activation of autophagy. Further, the inhibition of autophagy following chloroquine or bafilomycin A1 treatment reduced the anti-viral effect of budesonide against HRV, suggesting that the antiviral activity of budesonide was mediated via autophagy. The results suggest that budesonide represents a promising antiviral and anti-inflammatory drug candidate for the treatment of human rhinovirus infection.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:In-Data-Review

  4 / 5585 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29210513
[Au] Autor:Ha T; Valentine R; Moratti S; Hanton L; Robinson S; Wormald PJ
[Ad] Address:Department of Surgery-Otorhinolaryngology, Head and Neck Surgery, University of Adelaide, Adelaide, Australia.
[Ti] Title:The efficacy of a novel budesonide chitosan gel on wound healing following endoscopic sinus surgery.
[So] Source:Int Forum Allergy Rhinol;8(3):435-443, 2018 Mar.
[Is] ISSN:2042-6984
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Adhesion formation and ostial stenosis are common causes of surgical failure after endoscopic sinus surgery (ESS). Postoperative topical steroid application has been shown to improve wound healing. Chitosan-dextran gel (CD gel) is an effective hemostatic nasal dressing. This study aims to determine the effect of the addition of budesonide to CD gel on postoperative ostial stenosis and adhesion formation following ESS. METHODS: This prospective, blinded, randomized controlled trial was conducted between October 2012 and April 2015. Thirty-six patients over 18 years undergoing ESS were randomized to receive either: no treatment, CD gel, CD gel with 1 mg/ 2 mL budesonide, or topical steroid cream to their left or right sinuses (different treatment each side). Each sinus ostium and endoscopic features of wound healing was measured intraoperation, and 2 weeks, 3 months, and 12 months postoperation. RESULTS: Data was analyzed using the analysis of variance (ANOVA) and post hoc Tukey honestly significant difference (HSD) tests. There was a significant reduction in stenosis within all 3 sinuses ostia sites when CD + budesonide was compared to control, with the greatest effect seen at 12 months: The mean ± standard deviation (SD) percentage of baseline areas at 12 months were 76% ± 6.2% vs 37% ± 23.5%, 76% ± 6.3% vs 52% ± 4.9%, and 83% ± 6.5% vs 58% ± 5.0% (all p < 0.05), for CD + budesonide compared to control in the frontal, sphenoid, and maxillary sinuses, respectively. The incidence of adhesions was 4% in the CD + budesonide group compared to 15% in the control group. CONCLUSION: This study has shown that CD gel, when combined with topical budesonide solution, improves long-term sinus ostial patency and prevents ostial stenosis post-ESS.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:In-Data-Review
[do] DOI:10.1002/alr.22057

  5 / 5585 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29502560
[Au] Autor:Akturk HK; Chindris AM; Hines JM; Singh RJ; Bernet VJ
[Ad] Address:Department of Endocrinology, Mayo Clinic, Jacksonville, FL. Electronic address: kaanakturk@yahoo.com.
[Ti] Title:Over-the-Counter "Adrenal Support" Supplements Contain Thyroid and Steroid-Based Adrenal Hormones.
[So] Source:Mayo Clin Proc;93(3):284-290, 2018 Mar.
[Is] ISSN:1942-5546
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:OBJECTIVE: To assess whether dietary supplements that are herbal and/or animal-derived products, marketed for enhancing metabolism or promoting energy, "adrenal fatigue," or "adrenal support," contain thyroid or steroid hormones. METHODS: Twelve dietary adrenal support supplements were purchased. Pregnenolone, androstenedione, 17-hydroxyprogesterone, cortisol, cortisone, dehydroepiandrosterone sulfate, synthetic glucocorticoids (betamethasone, dexamethasone, fludrocortisone, megestrol acetate, methylprednisolone, prednisolone, prednisone, budesonide, and triamcinolone acetonide) levels were measured twice in samples in a blinded fashion. This study was conducted between February 1, 2016, and November 1, 2016. RESULTS: Among steroids, pregnenolone was the most common hormone in the samples. Budesonide, 17-hydroxyprogesterone, androstenedione, cortisol, and cortisone were the others in order of prevalence. All the supplements revealed a detectable amount of triiodothyronine (T3) (63-394.9 ng/tablet), 42% contained pregnenolone (66.12-205.2 ng/tablet), 25% contained budesonide (119.5-610 ng/tablet), 17% contained androstenedione (1.27-7.25 ng/tablet), 8% contained 17-OH progesterone (30.09 ng/tablet), 8% contained cortisone (79.66 ng/tablet), and 8% contained cortisol (138.5 ng/tablet). Per label recommended doses daily exposure was up to 1322 ng for T3, 1231.2 ng for pregnenolone, 1276.4 ng for budesonide, 29 ng for androstenedione, 60.18 ng for 17-OH progesterone, 277 ng for cortisol, and 159.32 ng for cortisone. CONCLUSION: All the supplements studied contained a small amount of thyroid hormone and most contained at least 1 steroid hormone. This is the first study that measured thyroid and steroid hormones in over-the-counter dietary "adrenal support" supplements in the United States. These results may highlight potential risks of hidden ingredients in unregulated supplements.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[St] Status:In-Data-Review

  6 / 5585 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29501934
[Au] Autor:Zhang X; Bao W; Fei X; Zhang Y; Zhang G; Zhou X; Zhang M
[Ad] Address:Department of Respiratory Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
[Ti] Title:Progesterone attenuates airway remodeling and glucocorticoid resistance in a murine model of exposing to ozone.
[So] Source:Mol Immunol;96:69-77, 2018 Mar 01.
[Is] ISSN:1872-9142
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Airway remodeling is a vital component of chronic obstructive pulmonary disease (COPD). Despite the broad anti-inflammation effects of glucocorticoids, they exhibit relatively little therapeutic benefit in COPD, indicating the accelerating demands of new agents for COPD. We aim to explore the effect of progesterone on airway remodeling in a murine modeling of exposing to ozone and to further examine the potential effect of progesterone on glucocorticoid insensitivity. C57/BL6 mice were exposed to ozone for 12 times over 6 weeks, and were administered with progesterone alone or combined with budesonide (BUD) after each exposure until the 10th week. The peribronchial collagen deposition was measured. The protein levels of MMP8 and MMP9 in bronchoalveolar lavage fluid (BALF) and lungs were assessed. Western blot analysis was used to detect the levels of hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF), a-smooth muscle actin (α-SMA), glycogen synthase kinase-3ß (GSK-3ß). The expression of VEGF and histone deacetylase 2 (HDAC2) in the lung were determined by Immunohistochemical analyses. We observe that progesterone attenuates the peribronchial collagen deposition, as well as the expression of MMP8, MMP9, HIF-1α, VEGF, α-SMA, and GSK-3ß in BALF or lung tissues. Progesterone or BUD monotherapy has no effect on HDAC2 production. Progesterone combines with BUD induce dramatically enhanced effects. Thus, these results demonstrate novel roles of progesterone for the pathogenesis and airway remodeling in COPD. Progesterone plus BUD administration exerts more significant inhibition on airway remodeling with dose-independent. Additionally, progesterone may, to some extent, improve the glucocorticoid insensitivity.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180304
[Lr] Last revision date:180304
[St] Status:Publisher

  7 / 5585 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29489916
[Au] Autor:Zhao S; Yang Q; Yu Z; Lv Y; Zhi J; Gustin P; Zhang W
[Ad] Address:Shanghai Jiao Tong University School of Medicine, Shanghai, China.
[Ti] Title:Protective effects of tiotropium alone or combined with budesonide against cadmium inhalation induced acute neutrophilic pulmonary inflammation in rats.
[So] Source:PLoS One;13(2):e0193610, 2018.
[Is] ISSN:1932-6203
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:As a potent bronchodilator, the anti-inflammatory effects of tiotropium and its interaction with budesonide against cadmium-induced acute pulmonary inflammation were investigated. Compared to values obtained in rats exposed to cadmium, cytological analysis indicated a significant decrease of total cell and neutrophil counts and protein concentration in bronchoalveolar lavage fluid (BALF) in rats pretreated with tiotropium (70µg/15ml or 350µg/15ml). Zymographic tests showed a decrease of MMP-2 activity in BALF in rats pretreated only with high concentration of tiotropium. Histological examination revealed a significant decrease of the severity and extent of inflammatory lung injuries in rats pretreated with both tested concentrations of tiotropium. Though tiotropium (70µg/15ml) or budesonide (250µg/15ml) could not reduce cadmium-induced bronchial hyper-responsiveness, their combination significantly decreased bronchial contractile response to methacholine. These two drugs separately decreased the neutrophil number and protein concentration in BALF but no significant interaction was observed when both drugs were combined. Although no inhibitory effects on MMP-2 and MMP-9 was observed in rats pretreated with budesonide alone, the combination with the ineffective dose of tiotropium induced a significant reduction on these parameters. The inhibitory effect of tiotropium on lung injuries was not influenced by budesonide which alone induced a limited action on the severity and extent of inflammatory sites. Our findings show that tiotropium exerts anti-inflammatory effects on cadmium-induced acute neutrophilic pulmonary inflammation. The combination of tiotropium with budesonide inhibits cadmium-induced inflammatory injuries with a synergistic interaction on MMP-2 and MMP-9 activity and airway hyper-responsiveness.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180228
[Lr] Last revision date:180228
[St] Status:In-Data-Review
[do] DOI:10.1371/journal.pone.0193610

  8 / 5585 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29400090
[Au] Autor:Lin J; Zhou X; Wang C; Liu C; Cai S; Huang M
[Ad] Address:a Department of Pulmonary and Critical Care Medicine , China-Japan Friendship Hospital , Beijing , China.
[Ti] Title:Symbicort® Maintenance and Reliever Therapy (SMART) and the evolution of asthma management within the GINA guidelines.
[So] Source:Expert Rev Respir Med;12(3):191-202, 2018 Mar.
[Is] ISSN:1747-6356
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:INTRODUCTION: The Global Initiative for Asthma (GINA) annual report summarizes the latest evidence for asthma management. GINA recommends stepwise pharmacological treatment, advocating inhaled corticosteroids (ICS) plus rapid, long-acting ß -agonists (LABA) delivered in a single inhaler for maintenance and relief at Steps 3 (moderate persistent asthma requiring 1-2 controllers plus as-needed reliever), 4 (severe persistent asthma requiring ≥2 controllers plus as-needed reliever), and 5 (higher level care and/or add-on treatment). Areas covered: Randomized controlled trials and real-world evidence demonstrate that flexibly dosed budesonide/formoterol for maintenance and relief (Symbicort® Maintenance And Reliever Therapy [SMART]) is associated with reductions in severe exacerbations, prolongs time to first exacerbation, and provides fast symptom relief. Expert commentary: SMART provides greater or equal levels of sustained asthma control than similar or higher fixed doses of ICS/LABA plus short-acting ß -agonist (SABA) as needed or higher ICS plus SABA as needed, with lower overall ICS doses and cost. The simplified dosing strategy may improve adherence and overall asthma control but relies on patient education. Budesonide/formoterol as needed in mild asthma (patients qualifying for regular low-dose ICS) is currently under investigation in two double-blind randomized studies, SYGMA1/2 (NCT02149199/NCT02224157), comparing budesonide/formoterol as needed with budesonide plus SABA and SABA alone.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180228
[Lr] Last revision date:180228
[St] Status:In-Data-Review
[do] DOI:10.1080/17476348.2018.1429921

  9 / 5585 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Clinical Trials Registry
Clinical Trials Registry
Full text

[PMID]: 29320647
[Au] Autor:Bassler D; Shinwell ES; Hallman M; Jarreau PH; Plavka R; Carnielli V; Meisner C; Engel C; Koch A; Kreutzer K; van den Anker JN; Schwab M; Halliday HL; Poets CF; Neonatal European Study of Inhaled Steroids Trial Group
[Ad] Address:From the Department of Neonatology, University Hospital Zurich, University of Zurich, Zurich (D.B.), and the Division of Pediatric Pharmacology and Pharmacometrics, University of Basel Children's Hospital, Basel (J.N.A.) - both in Switzerland; Ziv Medical Center, Faculty of Medicine in the Galilee,
[Ti] Title:Long-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia.
[So] Source:N Engl J Med;378(2):148-157, 2018 01 11.
[Is] ISSN:1533-4406
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: The long-term effects on neurodevelopment of the use of inhaled glucocorticoids in extremely preterm infants for the prevention or treatment of bronchopulmonary dysplasia are uncertain. METHODS: We randomly assigned 863 infants (gestational age, 23 weeks 0 days to 27 weeks 6 days) to receive early (within 24 hours after birth) inhaled budesonide or placebo. The prespecified secondary long-term outcome was neurodevelopmental disability among survivors, defined as a composite of cerebral palsy, cognitive delay (a Mental Development Index score of <85 [1 SD below the mean of 100] on the Bayley Scales of Infant Development, Second Edition, with higher scores on the scale indicating better performance), deafness, or blindness at a corrected age of 18 to 22 months. RESULTS: Adequate data on the prespecified composite long-term outcome were available for 629 infants. Of these infants, 148 (48.1%) of 308 infants assigned to budesonide had neurodevelopmental disability, as compared with 165 (51.4%) of 321 infants assigned to placebo (relative risk, adjusted for gestational age, 0.93; 95% confidence interval [CI], 0.80 to 1.09; P=0.40). There was no significant difference in any of the individual components of the prespecified outcome. There were more deaths in the budesonide group than in the placebo group (82 [19.9%] of 413 infants vs. 58 [14.5%] of 400 infants for whom vital status was available; relative risk, 1.37; 95% CI, 1.01 to 1.86; P=0.04). CONCLUSIONS: Among surviving extremely preterm infants, the rate of neurodevelopmental disability at 2 years did not differ significantly between infants who received early inhaled budesonide for the prevention of bronchopulmonary dysplasia and those who received placebo, but the mortality rate was higher among those who received budesonide. (Funded by the European Union and Chiesi Farmaceutici; ClinicalTrials.gov number, NCT01035190 .).
[Mh] MeSH terms primary: Bronchopulmonary Dysplasia/prevention & control
Budesonide/administration & dosage
Developmental Disabilities/epidemiology
Glucocorticoids/administration & dosage
Infant, Extremely Premature
[Mh] MeSH terms secundary: Administration, Inhalation
Blindness/epidemiology
Cerebral Palsy/epidemiology
Cognition Disorders/epidemiology
Female
Follow-Up Studies
Gestational Age
Hearing Loss/epidemiology
Humans
Infant, Newborn
Infant, Premature, Diseases/mortality
Male
[Pt] Publication type:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:0 (Glucocorticoids); 51333-22-3 (Budesonide)
[Em] Entry month:1801
[Cu] Class update date: 180228
[Lr] Last revision date:180228
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180111
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMoa1708831

  10 / 5585 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29481835
[Au] Autor:Saari A; Virta LJ; Dunkel L; Sankilampi U
[Ad] Address:Department of Pediatrics, School of Medicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland; Department of Pediatrics, Kuopio University Hospital, Kuopio, Finland. Electronic address: antti.saari@kuh.fi.
[Ti] Title:inhaled Corticosteroids in Infants and Toddlers Attenuate Linear Growth.
[So] Source:J Allergy Clin Immunol;, 2018 Feb 23.
[Is] ISSN:1097-6825
[Cp] Country of publication:United States
[La] Language:eng
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180226
[Lr] Last revision date:180226
[St] Status:Publisher


page 1 of 559 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information